As sales of Provenge continued to disappoint in the first half of the year, Dendreon's new CEO opted to trigger another big restructuring at the Seattle-based biotech, with plans to cut 600 jobs and shutter one of its three manufacturing sites in an effort to slash his way to profitability.
John Johnson has a good reason today to be thankful for his new job at Dendreon: He won't have to face the music at Savient.
A pair of Dendreon veterans has swooped in to take charge of the troubled Swiss biotech Mymetics with ambitious plans.
Dendreon's pioneering cancer vaccine, Provenge, is under fire again.
The news just keeps getting better for Johnson & Johnson's new prostate cancer drug Zytiga (abiraterone).
Therapeutic vaccines could prove to be a good way to tackle cancer. A few shots and--it is hoped--only a few side effects, rather than long treatments with traditional chemotherapy drugs that make...
In the course of one short year, Dendreon CEO Mitch Gold went from biotech hero to zero as the long-anticipated rollout of the groundbreaking cancer vaccine Provenge stumbled badly out of the gate.
Targeting a variety of tumor types, the Roswell Park Cancer Institute has begun recruiting patients for an early-stage clinical trial to test an experimental cancer vaccine. The vaccine, or...
Merck KGaA and Oncothyreon ($ONTY) will learn soon whether their lung cancer vaccine has a shot at being one of the next bright lights in the cancer immunotherapy arena, with an interim analysis set
A team of Massachusetts researchers has figured out how to arm nanotech with chemotherapy drugs and successfully target it to hit prostate cancer cells, which absorbed the package well. Brigham and